Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Carbohydrate doai
Reexamination Certificate
2005-11-01
2005-11-01
Chen, Shin-Lin (Department: 1632)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Carbohydrate doai
C536S023500, C435S069300, C435S455000
Reexamination Certificate
active
06960570
ABSTRACT:
Compositions and methods for the therapy and diagnosis of cancer, particularly lung cancer, are disclosed. Illustrative compositions comprise one or more lung tumor polypeptides, immunogenic portions thereof, polynucleotides that encode such polypeptides, antigen presenting cell that expresses such polypeptides, and T cells that are specific for cells expressing such polypeptides. The disclosed compositions are useful, for example, in the diagnosis, prevention and/or treatment of diseases, particularly lung cancer.
REFERENCES:
patent: 5589579 (1996-12-01), Torczynski et al.
patent: 5705159 (1998-01-01), Irie et al.
patent: 5783422 (1998-07-01), Suminami et al.
patent: 6200764 (2001-03-01), Carney
patent: 6297364 (2001-10-01), Chen et al.
patent: 679716 (1995-11-01), None
patent: 0695760 (1996-02-01), None
patent: 1033401 (2000-09-01), None
patent: 1130094 (2001-09-01), None
patent: WO 91/18926 (1991-12-01), None
patent: WO 94/06929 (1994-03-01), None
patent: WO 95/21862 (1995-08-01), None
patent: WO 96/02552 (1996-02-01), None
patent: WO 96/28473 (1996-09-01), None
patent: WO 96/30389 (1996-10-01), None
patent: WO 97/07244 (1997-02-01), None
patent: WO 98/35985 (1998-08-01), None
patent: WO 98/46788 (1998-10-01), None
patent: WO 99/38973 (1999-08-01), None
patent: WO 99/46594 (1999-09-01), None
patent: WO 99/47674 (1999-09-01), None
patent: WO 99/54738 (1999-10-01), None
patent: WO 00/61612 (2000-10-01), None
patent: WO 01/47944 (2001-07-01), None
patent: WO 01/55322 (2001-08-01), None
patent: WO 01/57272 (2001-08-01), None
patent: WO 01/57275 (2001-08-01), None
patent: WO 01/57276 (2001-08-01), None
patent: WO 01/57277 (2001-08-01), None
patent: WO 01/75067 (2001-10-01), None
Chen, Shen-Lin et al., “Isolation and characterization of a novel gene expressed in multiple cancers,”Oncogene 12: 741-751, 1996.
Güre, A.O. et al., “Human Lung Cancer Antigens Recognized by Autologous Antibodies: Definition of a Novel cDNA Derived from the Tumor Suppressor,”Cancer Research 58: 1034-1041, Mar. 1, 1998.
GenBank Database, Accession No. AAB82295, Oct. 30, 1997.
GenBank Database, Accession No. AAB97457, Jan. 22, 1998.
GenBank Database, Accession No. AAC18597, Jun. 3, 1998.
GenBank Database, Accession No. AAC18598, Jun. 3, 1998.
GenBank Database, Accession No. AAC35208, May 13, 1997.
GenBank Database, Accession No. AAC41285, May 13, 1998.
GenBank Database, Accession No. AAC65900, Oct. 10, 2003.
GenBank Database, Accession No. AAD09223, Jan. 26, 1999.
GenBank Database, Accession No. AAD09827, Jan. 26, 1999.
GenBank Database, Accession No. AAD09828, Jan. 26, 1999.
GenBank Database, Accession No. AAF37203, Mar. 2, 2000.
GenBank Database, Accession No. AC005082, Sep. 8, 1999.
GenBank Database, Accession No. AC021876, Jan. 21, 2000.
GenBank Database, Accession No. AC079780, Feb. 21, 2002.
GenBank Database, Accession No. AC092447, Jul. 4, 2001.
GenBank Database, Accession No. AF117108, Jan. 26, 1999.
GenBank Database, Accession No. AF198254, Mar. 2, 2000.
GenBank Database, Accession No. AL023775, Nov. 23, 1999.
GenBank Database, Accession No. BAB19755, Dec. 20, 2000.
GenBank Database, Accession No. BAB27779, Feb. 8, 2001.
GenBank Database, Accession No. BAB27848, Feb. 8, 2001.
GenBank Database, Accession No. BC019258, Dec. 19, 2001.
GenBank Database, Accession No. O00425, Jul. 1, 1997.
GenBank Database, Accession No. NM_006547, Nov. 1, 2000.
GenBank Database, Accession No. NP_034081, Jan. 25, 2000.
GenBank Database, Accession No. NP_006537, Aug. 10, 1999.
GenBank Database, Accession No. NP_006538, Nov. 1, 2000.
GenBank Database, Accession No. NP_006539, Aug. 10, 1999.
GenBank Database, Accession No. NP_571566, Feb. 20, 2002.
GenBank Database, Accession No. NP_076159, Feb. 19, 2001.
GenBank Database, Accession No. U76705, Jan. 26, 1999.
GenBank Database, Accession No. U97188, May 20, 1997.
GenBank Database, Accession No. XM_004780, Nov. 16, 2000.
GenBank Database, Accession No. XP_004780, Nov. 16, 2000.
Geneseq Database (Thomson Derwent), Accession AAL28189, Jan. 24, 2002.
Geneseq Database (Thomson Derwent), Accession AAM93826, Nov. 6, 2001.
Geneseq Database (Thomson Derwent), Accession AAT26750, Oct. 23, 1996.
Geneseq Database (Thomson Derwent), Accession AAU16161, Nov. 7, 2001.
Geneseq Database (Thomson Derwent), Accession AAU16163, Nov. 7, 2001.
Geneseq Database (Thomson Derwent), Accession AAU16164, Nov. 7, 2001.
Geneseq Database (Thomson Derwent), Accession AAU16166, Nov. 7, 2001.
Geneseq Database (Thomson Derwent), Accession AAU16579, Nov. 7, 2001.
Geneseq Database (Thomson Derwent), Accession AAU16583, Nov. 7, 2001.
Ackermann, R. “Monoclonal antibodies,”Human Cell 1(1):46-53, 1988 (Abstract Only; PubMed ID:3154013).
Arceci, R.J., “The potential for antitumor vaccination in acute myelogenous leukemia,”J. Mol. Med. 76: 80-93, 1998.
Bergers and Coussens, “Extrinsic regulators of epithelial tumor progression: metalloproteinases,”Current Opinion in Genetics&Developments 10: 120-127, 200.
Bodey, B. et al., “Failure of Cancer Vaccines: The Significant Limitations of this Approach to Immunotherapy,”Anticancer Research 20: 2665-2676, 2000.
Boon, T., “Toward a Genetic Analysis of Tumor Rejection Antigens,”Advances in Cancer Research 58: 177-210, 1992.
Eck and Wilson, “Gene-Based Therapy,” inGoodman&Gilman's The Pharmacological Basis of Therapeutics, 9thEdition, McGraw-Hill, New York, 1996, pp. 77-101.
Ezzell, C., “Cancer ‘Vaccines’: An Idea Whose Time Has Come?”The Journal of NIH Research 7: 46-49, Jan. 1995.
Greenspan and Cooper, “Complementarity, specificity and the nature of epitopes and paratopes in multivalent interactions,”Immunology Today 16(5): 226-230, 1995.
Gura, T., “System for Identifying New Drugs Are Often Faulty,”Science 278: 1041-1042, Nov. 7, 1997.
Kaye, F.J. et al. “A single amino acid substitution results in a retinoblastoma protein defective in phosphorylation and oncoprotein binding,”Proc. Natl. Acad. Sci. USA 87: 6922-6926, Sep. 1990.
Lee, K-H. et al., “Increased Vaccine-Specific T Cell Frequency After Peptide-Based Vaccination Correlates with Increased Susceptibility to In Vitro Stimulation But Does Not Lead to Tumor Regression,”The Journal of Immunology 163: 6292-6300, 1999.
Müeller-Pillasch, F. et al., “Cloning of a gene highly overexpressed in cancer coding for a novel KH-domain containing protein,”Oncogene 14: 2729-2733, 1997.
Nielsen, J. et al., “A Family of Insulin-Like Growth Factor II mRNA-Binding Proteins Represses Translation in Late Development,”Molecular and Cellular Biology 19(2): 1262-1270, Feb. 1999.
Radoja and Frey, “Cancer-induced Defective Cytotoxic T Lymphocyte Effector Function: Another Mechanism How Antigenic Tumors Escape Immune-mediated Killing,”Molecular Medicine 6(6): 465-479, Jun. 2000.
Rudinger, J., “Characteristics of the amino acids as components of a peptide hormone sequence,” inPeptide Hormones, Parsons, J.A. (ed.), University Park Press, Baltimore MD, Jun. 1976, pp. 1-7.
Sjölander, A. et al., “Kinetics, localization and cytokine profile of T cell responses to immune stimulating complexes (iscoms) containing human influenza virus envelope glycoproteins,”Vaccine 15(9): 1030-1038, 1997.
Skolnick and Fetrow, “From genes to protein structure and function: novel applications of computational approaches in the genomic era,”Trends in Biotechnology 18: 34-39, Jan. 2000.
Spitler, L.E., “Cancer Vaccines: The Interferon Analogy,”Cancer Biotherapy 10(1): 1-3, 1995.
Stern, P.S., “Predicting antigenic sites on proteins,”Trends in Biotechnology 9: 163-169, May 1991.
Timmerman and Levy, “Dendritic Cell Vaccines for Cancer Immunotherapy,”Annu. Rev. Med. 50: 507-529, 1999.
Wong, C.P. et al., “TCR Vaccines Against T Cell Lymphoma: QS-21 and IL-12 Adjuvants Induce a Protective CD8+T Cell Response,”The Journal of I
Foy Teresa M.
Henderson Robert A.
Wang Tongtong
Chen Shin-Lin
Corixa Corporation
Seed IP Law Group PLLC
LandOfFree
Compositions and methods for the therapy and diagnosis of... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Compositions and methods for the therapy and diagnosis of..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Compositions and methods for the therapy and diagnosis of... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3474398